

Special Issue

Antimicrobial Agents in Oral Diseases: Prophylaxis and Therapy between New and Old Molecules

Message from the Guest Editor

Antibiotic resistance represents a huge problem that the scientific community is called upon to tackle as a matter of priority. Safeguarding the effectiveness of old antimicrobial agents is fundamental today, as is the need to discover new ones. Studies will be pivotal to further elucidate the mechanism of action of old molecules to better understand, counteract, and prevent the spread of resistant bacteria. Research is also aimed at identifying new ones as well as proposing molecules which are capable of acting as adjuvants.

Common oral diseases (e.g., orofacial infection, periodontitis) in particular are treated using the support of antibiotics and antiseptics, representing the most prescribed medications by dentists, who are, thus, called to the fore to fight inappropriate prescriptions in their routine practice. This Special Issue will publish papers focusing on the management of oral diseases with a particular focus on the activity of old and new antiseptics and antibiotics, on the use of these medications in dental setting, and on the education of dental professionals regarding their correct prescription.

Guest Editor

Dr. Elena Varoni

Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy

Deadline for manuscript submissions

closed (31 January 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/70800

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)